Log in |
Hee Seung Kim MD, Chel Hun Choi MD, PhD, Myong-Chul Lim MD, PhD, Suk-Joon Chang MD, PhD, Yong Beom Kim MD, PhD, Min A. Kim MD, PhD, Tae-Jin Kim MD, PhD, Sang-Yoon Park MD, PhD, Byoung-Gie Kim MD, PhD, Yong Sang Song MD, PhD, Duk-Soo Bae MD, PhD, Jae Weon Kim MD, PhD
View full article HTML | View full article PDF | Download Citation
To determine the safe criteria for less radical trachelectomy to treat patients with early-stage cervical cancer.
We reviewed medical records and pathologic slides of 65 patients with International Federation of Gynecology and Obstetrics (FIGO) stage IA–IB1 cervical cancer. The safe criteria for less radical trachelectomy were determined by using three factors such as tumor size ≤1 cm, stromal invasion ≤5 mm, and no lymphovascular space invasion (LVSI) for minimizing parametrial involvement, lymph node metastasis (LNM), and the need of adjuvant radiotherapy. The diagnostic values were investigated by calculating specificity, negative predictive value for no parametrial involvement, no LNM, and no need of adjuvant radiotherapy.
The median age was 32 years (range 22–44 years), and the median duration of follow-up was 26 months (range 2–103 months). Among seven single or combined factors for the safe criteria, (1) tumor size ≤1 cm, (2) tumor size ≤1 cm and stromal invasion ≤5 mm, (3) tumor size ≤1 cm and no LVSI, (4) tumor size ≤1 cm, stromal invasion ≤5 mm, and no LVSI did not show parametrial involvement, LNM, and the need of adjuvant radiotherapy. In particular, tumor size ≤1 cm showed the highest specificity (28.1–29.5%) and negative predictive value (100%). In spite of no difference in progression-free survival (PFS) between tumor size ≤1 cm and >1 cm (P = 0.22), tumor size ≤1 cm showed better PFS without disease recurrence than tumor size >1 cm (2-year PFS, 100% vs. 90%).
Less radical trachelectomy may be safe in patients with early-stage cervical cancer who have tumor size ≤1 cm.
Go to Issue Contents
Add this article to your Personal Archive
Effective January 2013, there will be a processing fee of $50 USD for each initial new submission of an Annals article, excluding editorials. Submitted new manuscripts will not enter the review process until the submission fee has been paid. . There will be no processing fee associated with resubmitted manuscripts.
HIGHLIGHTED VIDEO OF THE MONTH
Lymphatic Mapping and Sentinel Node Biopsy in the Colonic Mesentery by Natural Orifice Transluminal Endoscopic Surgery (NOTES) by R. A. Cahill MD, FRCS, S. Perretta MD, J. Leroy MD, B. Dallemagne MD, and J. Marescaux MD, FRCS, FACS. Annals of Surgical Oncology. Volume 15, Number 10, DOI: 10.1245/s10434-008-9952-8
Annals of Surgical Oncology is copyrighted by the Society of Surgical Oncology
© Springer Healthcare Ltd. A part of Springer Science+Business Media